Fusion Antibodies (LON:FAB) Sets New 1-Year High – Here’s Why

Shares of Fusion Antibodies plc (LON:FAB) reached a new 52-week high on Friday . The company traded as high as GBX 10.25 ($0.13) and last traded at GBX 10.23 ($0.13), with a volume of 3693715 shares changing hands. The stock had previously closed at GBX 8.15 ($0.10).

Fusion Antibodies Price Performance

The firm has a 50-day simple moving average of GBX 5.48 and a 200-day simple moving average of GBX 4.19. The firm has a market capitalization of £9.76 million, a PE ratio of -255.85 and a beta of 0.49. The company has a debt-to-equity ratio of 2.40, a current ratio of 3.87 and a quick ratio of 2.36.

Insider Buying and Selling

In related news, insider Adrian Kinkaid bought 83,728 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The shares were bought at an average cost of GBX 4 ($0.05) per share, with a total value of £3,349.12 ($4,160.40). 11.39% of the stock is currently owned by insiders.

About Fusion Antibodies

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services.